Verastem (NASDAQ:VSTM) Research Coverage Started at Guggenheim

Guggenheim started coverage on shares of Verastem (NASDAQ:VSTM – Free Report) in a report issued on Monday, Marketbeat Ratings reports. The firm issued a buy rating and a $13.00 price target on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on VSTM. Truist Financial lowered their target price on […]

Leave a Reply

Your email address will not be published.

Previous post Willis Towers Watson Public (NASDAQ:WTW) Given New $365.00 Price Target at Truist Financial
Next post Truist Financial Cuts Viper Energy (NASDAQ:VNOM) Price Target to $54.00